Similar companies
Income Statement (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 25.1B | 127322.4% |
| Net Income | -19.7B | 101515% |
| EBITDA | -25.1B | 134537.9% |
Balance Sheet (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 87.3B | 76997.9% |
| Total Liabilities | 36B | 80497.9% |
| Total Equity | 51.3B | 74714.4% |
| Shares Outstanding | 39M | 42.2% |
Cash Flow (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -26.9B | 136566.8% |
| Cash from financing | 1.03B | 3426.9% |
EPS
Financial Highlights for Inovio Pharmaceuticals in Q1 '25
Operating Expenses for this period were 25.1B, showing a 127322.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -19.7B, showing a -101515% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -25.1B, showing a -134537.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Inovio Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
